Number needed to screen: Development of a statistic for disease screening

British Medical Journal

Volumn 317, Issue 7154, 1998, Pages 307-312

  Rembold, Christopher M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ARTICLE; BIOSTATISTICS; BREAST CANCER; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; HEMATOCRIT; HUMAN; HYPERTENSION; MAMMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCREENING; SCREENING TEST;

EID: 0032146983     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.317.7154.307     Document Type: Article

References (31)

1. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Linqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet 1993;341:973-8.
2. Miller AB, Baines CJ, To T, Wall C. Canadian national breast cancer screening study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 1992;147:1459-76.
3. Miller AB, Baines CJ, To T, Wall C. Canadian national breast cancer screening study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J 1992;147:1477-88.
4. Soloman MJ, McLeod RS. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Can Med Assoc J 1994;150:1961-70.
5. Medical Research Council working party. Medical Research Council trial in the treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
6. Rembold CM. A number needed to treat (NNT) analysis of the prevention of myocardial infarction and death by dyslipidemic therapy. J Fam Pract 1996;42:577-86.
7. Armitage P, Berry G. Statistical methods in medical research, 3rd ed. Oxford: Blackwell Scientific, 1994.
8. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-5.
9. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20.
10. United States Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension - results of a ten-year intervention trial. Circ Res 1977;40:I98-105.
11. Perry HM, Goldman AI, Lavin MA, Schnaper HW, Fitz AE, Frohlich ED. et al. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasiblity trial. NY Acad Sci 1978;304:267-92.
12. Helgeland A, Treatment of mild hypertension: a five year controlled drug trial. Am J Med 1980;69:725-32.
13. Report by the management committee. The Australian therapuetic trial in mild hypertension. Lancet 1980;1:1261-7.
14. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet 1985;1:1349-54.
15. Medical Research Council working party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.
16. Hypertension Detection and Followup Program Cooperative Group. Five-year findings of the hypertension detection and followup program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;212:2562-71.
17. Multiple risk factor intervention trial research group. Multiple risk factor intervention trial risk factor changes and morlality results. JAMA 1982;248:1465-77.
18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-64.
19. Dahlof B, Lindhold LH, Hansson L, Schersten B, Ekbom T, Wester P. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
20. The International Prospective Primary Prevention Study in Hypertension Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertension 1985;3:379-92.
21. Pravastatin Multination Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
23. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P. Helsinki heart study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
24. Committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;10:1069-118.
25. Steering committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-35.
26. Peto R, Gray R, Collins R, Wheatley, K, Hennekens C, Jamrozik K, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
27. Holme I, Hjermann I, Helgeland A, Leren P. The Oslo study: diet and anti-smoking advice. Prev Med 1985;11:279-92.
28. Dorr AE, Gundersen K, Schneider R, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chronic Dis 1978;31:5-11.
29. Lipid research clinic program. The lipid research clinic coronary primary prevention trial results. JAMA 1984;251:351-64.
30. Nieto FG, Alonso J, Chambless LE, Zhong M, Ceraso M, Romm FJ, et al. Population awareness and control of hypertension and hypercholesterolemia. The atherosclerosis risk in communities studies. Arch Intern Med 1995;155:677-84.
31. Kine LK, Laird N, Hewitt P, Chalmers TC. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989;262:3037-40.